<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Key opportunities include first-line adoption in lower-risk MDS, deeper penetration in RS-negative patients, broader use across anemia indications, expansion into alpha-thalassemia and myelofibrosis, earlier treatment sequencing, and wider international uptake.Dublin, Sept. 10, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/6274362/reblozyl-sales-forecast-market-size-analysis?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=hsvrbw&amp;utm_campaign=2348667+-+REBLOZYL+Sales+Forecast+and+Market+Size+Analysis+2020-2034+%7c+New+Indications+Broaden+REBLOZYL+Market+Potential&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="REBLOZYL Sales Forecast, and Market Size Analysis - 2034">"REBLOZYL Sales Forecast, and Market Size Analysis - 2034"</a> has been added to ResearchAndMarkets.com's offering. The REBLOZYL sales forecast and market analysis report provides a comprehensive assessment of the therapy's commercial performance, clinical development, regulatory milestones and growth prospects through 2034. The analysis covers approved indications, including beta-thalassemia and myelodysplastic syndromes, alongside potential opportunities in myelofibrosis and alpha-thalassemia across the seven major markets: the United States, Germany, France, Italy, Spain, the United Kingdom and Japan. Key Factors Driving REBLOZYL Market Growth <ul><li>Expansion into first-line lower-risk MDS: REBLOZYL's expansion from second-line treatment into first-line treatment for anemia in adults with very low-, low- or intermediate-risk myelodysplastic syndromes requiring red blood cell transfusions has significantly increased its addressable market. In the Phase III COMMANDS trial, 58.5% of patients receiving REBLOZYL achieved red blood cell transfusion independence for at least 12 weeks with a concurrent hemoglobin increase of at least 1.5 g/dL, compared with 31.2% of patients receiving epoetin alfa.</li><li>Broader physician adoption: Positive clinical evidence, treatment guideline recommendations and label expansion have supported increased use of REBLOZYL as a frontline option for eligible lower-risk MDS patients. Continued penetration of the larger ring sideroblast-negative population and earlier treatment switching are expected to support further commercial growth.</li><li>Multiple therapeutic indications: REBLOZYL's use across several hematologic disorders diversifies its revenue base and expands utilization among hematologists. Regulatory approvals and commercial launches in the United States, Europe, Japan and other international markets are also increasing the eligible patient population.</li><li>Clinical differentiation: REBLOZYL promotes late-stage erythroid maturation by binding select transforming growth factor-beta superfamily ligands and reducing aberrant SMAD2/3 signaling. Its differentiated clinical profile has demonstrated meaningful improvements in transfusion independence and hemoglobin levels across pivotal studies, including MEDALIST, COMMANDS and INDEPENDENCE.</li><li>International commercial expansion: Increased first-line MDS penetration, geographic expansion and improved treatment sequencing are expected to remain important contributors to REBLOZYL revenue growth through the forecast period.</li></ul> Recent REBLOZYL Development In February 2026, Bristol Myers Squibb announced positive top-line results from the ex-US Phase II registrational study NCT05664737, which evaluated REBLOZYL, or luspatercept-aamt, versus placebo for the treatment of anemia in adults with alpha-thalassemia. This development may support the therapy's continued lifecycle expansion and strengthen its long-term market potential, subject to complete study results and regulatory review. REBLOZYL Drug and Clinical Overview REBLOZYL is a subcutaneously administered erythroid maturation agent used to treat anemia associated with selected hematologic disorders. It is administered once every three weeks and has demonstrated reductions in transfusion burden among eligible patients. Reported adverse events include fatigue, headache, musculoskeletal pain, diarrhea, hypertension and injection-site reactions. Monitoring may be required for blood pressure changes and thromboembolic risk. Developed by Bristol Myers Squibb in collaboration with Merck &amp; Co. outside certain territories, REBLOZYL has become an important treatment option for chronic anemia. Its market outlook is supported by clinical differentiation, expanded indications, physician adoption and continued investment in research and development. Scope of the REBLOZYL Market Report <ul><li>Historical, current and forecast REBLOZYL sales through 2034 across the seven major markets.</li><li>Market size analysis for approved and potential indications.</li><li>Mechanism of action, dosage, administration and clinical development assessment.</li><li>Regulatory milestones, expected launch timelines and geographic expansion.</li><li>REBLOZYL pricing, reimbursement, treatment costs and regional cost variations.</li><li>Patent coverage, potential generic entry and the anticipated effect on pricing.</li><li>Clinical trial analysis, including interventions, conditions, status and study timelines.</li><li>Competitive intelligence covering marketed therapies and late-stage pipeline products.</li><li>SWOT analysis, analyst perspectives and evaluation of commercial opportunities and risks.</li></ul> Competitive Landscape and Revenue Forecast The REBLOZYL market forecast evaluates projected sales, peak revenue potential, market positioning and competitive threats. The analysis compares REBLOZYL with established treatments and emerging therapies in beta-thalassemia, myelodysplastic syndromes, myelofibrosis and alpha-thalassemia. It also reviews efficacy, safety, pricing, reimbursement and product differentiation factors that may influence future uptake. Although broader adoption and indication expansion are expected to support growth, the market may be affected by competing late-stage therapies, changes in treatment guidelines, reimbursement restrictions and future patent expirations. The report assesses these factors to provide a balanced view of REBLOZYL's long-term commercial outlook. Key Strategic Questions Addressed <ul><li>What are the primary drivers and barriers affecting REBLOZYL market growth?</li><li>How is REBLOZYL performing clinically and commercially across its approved indications?</li><li>What sales are forecast through 2034 in the United States, Europe and Japan?</li><li>How could potential indications influence future revenue and market share?</li><li>Which marketed and emerging therapies present the strongest competitive challenge?</li><li>How do pricing, reimbursement and treatment costs vary by geography?</li><li>What regulatory, clinical and commercial milestones could affect future adoption?</li><li>How may patents and potential generic competition influence long-term sales?</li></ul> The REBLOZYL sales forecast and market report is designed to support pharmaceutical companies, investors, healthcare stakeholders and strategy teams evaluating therapeutic portfolios, competitive positioning and commercial opportunities in hematology. Its coverage of market trends, clinical differentiation, regulatory activity and forecast sales through 2034 provides a strategic view of REBLOZYL's evolving role across approved and potential indications. Key Topics Covered 1. Report Introduction 2. REBLOZYL Overview in approved indications like Beta-thalassaemia and Myelodysplastic syndromes; as well as potential indication like Myelofibrosis and Alpha-thalassaemia 2.1. Product Detail 2.2. REBLOZYL Clinical Development 2.2.1. REBLOZYL Clinical studies 2.2.2. REBLOZYL Clinical trials information 2.2.3. Safety and efficacy 2.3. Other Developmental Activities 2.4. Product Profile 3. REBLOZYL Competitive Landscape (Marketed Therapies) 4. Competitive Landscape (Late-stage Emerging REBLOZYL Therapies) 5. REBLOZYL Market Assessment 5.1. REBLOZYL Market Outlook in approved and potential indications 5.2. 7MM Analysis 5.2.1. REBLOZYL Market Size in the 7MM for approved and potential indications 5.3. Country-wise Market Analysis 5.3.1. REBLOZYL Market Size in the United States for approved and potential indications 5.3.2. REBLOZYL Market Size in Germany for approved and potential indications 5.3.3. REBLOZYL Market Size in France for approved and potential indications 5.3.4. REBLOZYL Market Size in Italy for approved and potential indications 5.3.5. REBLOZYL Market Size in Spain for approved and potential indications 5.3.6. REBLOZYL Market Size in the United Kingdom for approved and potential indications 5.3.7. REBLOZYL Market Size in Japan for approved and potential indications 6. REBLOZYL SWOT Analysis 7. Analysts' Views 8. Appendix 8.1. Bibliography 8.2. Report Methodology List of Tables Table 1: REBLOZYL, Clinical Trial Description, 2023 Table 2: REBLOZYL, General Description Table 3: Competitive Landscape (Marketed Therapies) Table 4: Competitive Landscape (Emerging Therapies) Table 5: REBLOZYL's pricing and cost Assumptions Table 6: REBLOZYL's Sales Analysis in the 7MM, in USD million (2020-2034) Table 7: REBLOZYL Market Size in the US, in USD million (2020-2034) Table 8: REBLOZYL Market Size in Germany, in USD million (2020-2034) Table 9: REBLOZYL Market Size in France, in USD million (2020-2034) Table 10: REBLOZYL Market Size in Italy, in USD million (2020-2034) Table 11: REBLOZYL Market Size in Spain, in USD million (2020-2034) Table 12: REBLOZYL Market Size in the UK, in USD million (2020-2034) Table 13: REBLOZYL Market Size in Japan, in USD million (2020-2034) List of Figures Figure 1: REBLOZYL's Sales Analysis in the 7MM, USD million (2020-2034) Figure 2: REBLOZYL Market Size in the United States, USD million (2020-2034) Figure 3: REBLOZYL Market Size in Germany, USD million (2020-2034) Figure 4: REBLOZYL Market Size in France, USD million (2020-2034) Figure 5: REBLOZYL Market Size in Italy, USD million (2020-2034) Figure 6: REBLOZYL Market Size in Spain, USD million (2020-2034) Figure 7: REBLOZYL Market Size in the United Kingdom, USD million (2020-2034) Figure 8: REBLOZYL Market Size in Japan, USD million (2020-2034) For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6274362/reblozyl-sales-forecast-market-size-analysis?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=hsvrbw&amp;utm_campaign=2348667+-+REBLOZYL+Sales+Forecast+and+Market+Size+Analysis+2020-2034+%7c+New+Indications+Broaden+REBLOZYL+Market+Potential&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/a5mktw</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/NzJiMmJhNzgtOTNlNC00M2IwLThiMGUtZWE2MzcyZWQ5ZmNkLTEwMjY3MzctMjAyNi0wOS0xMC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

REBLOZYL Sales Forecast and Market Size Analysis 2020-2034 | New Indications Broaden REBLOZYL Market Potential

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn